RedHill Biopharma Ltd. (RDHL) shares are trending up 5.86% to $8.85 in the pre-opening hours. Considering the past, we will study various developments that may have caused RDHL to move forward or backward. Within the past five business days, shares rose 7.32% percent and declined -14.95 percent. Somewhere during the previous quarter, the stock dropped -13.64 percent. In the six months ending July 31, 2007, the stock’s output increased 21.16%, while annual general production increased 42.18 percent. At the end of the calendar year, the Company is performing better than the beginning.
RedHill Biopharma Ltd., through its subsidiary RedHill Biopharma Israel Ltd., commercializes and develops pharmaceutical products.
- Looking For The Best Stocks To Buy For 2021? 3 Electric Vehicle Stocks To Watch
- 3 Best E-Commerce Stocks to Buy Now
What’s the latest…
The Company announced on January 14, 2021, that it had closed its previously announced underwritten offering of 3,188,776 American Depositary Shares (ADSs) of the Company for $7.84 per ADS. An ADS represents ten ordinary shares of the Company, each valued at NIS 0.01 per share.
RedHill Biopharma Ltd. (RDHL) revealed on January 12, 2021, that the underwriter has increased the size of the previously announced offer and agreed to buy 3,188,776 American Depositary Shares of the Company for $7.84 per ADS, less underwriting discounts and commissions. The closing of this offering is expected to occur on or about January 14, 2021, subject to satisfying the customary closing conditions. Each ADS represents ten ordinary shares of the Company, each worth NIS 0.01 per share.
Based on BTIG Research’s research note dated September 11, 2020, the stock was rated a Buy. The stock was rated a Strong Buy by WBB Securities in a research note published on July 12, 2019.